Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill expands a appropriation, compliance mandate, product standard provision: 2. It relies on appropriations, compliance mandates, and product standards. The main policy areas are Healthcare.
Who Benefits and How
The available clause analysis does not identify a specific beneficiary group.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Expands a appropriation, compliance mandate, product standard provision: 2.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for primary purpose and policy domains.
At a Glance
What This Bill Does
The bill expands a appropriation, compliance mandate, product standard provision: 2.
Key Policy Areas
Healthcare
Primary Purpose
The bill expands a appropriation, compliance mandate, product standard provision: 2.
Policy Domains
Sponsors
Legislative Progress
In CommitteeMr. Crapo (for himself, Mr. Bennet, Mr. Scott of South …
Read twice and referred to the Committee on Finance.
Introduced in Senate
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
Note: None identified - the bill has a simple structure with a single actor (Secretary of HHS) and clear definitions
Key Definitions
Terms defined in this bill
A test furnished to an individual for the concurrent detection of multiple cancer types across multiple organ sites on or after January 1, 2028, that: (A) is cleared under section 510(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; (B) is either (i) a genomic sequencing blood or blood product test that includes the analysis of cell-free nucleic acids, or (ii) a test based on samples of biological material that provides results comparable to those obtained with a test described in clause (i); and (C) the Secretary determines is reasonable and necessary for the prevention or early detection of an illness or disability and appropriate for individuals entitled to benefits under part A or enrolled under part B
Before January 1, 2031: equal to the payment amount for a multi-target stool screening DNA test (e.g., Cologuard). On or after January 1, 2031: the lesser of the stool test amount or the payment amount determined under section 1834A (Clinical Laboratory Fee Schedule)
For 2028: age 68 years. For each succeeding year: the age specified for the preceding year, increased by 1 year (so 69 in 2029, 70 in 2030, etc.). Frequency: once per 12 months. These limitations do not apply if USPSTF recommends the test with grade A or B
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology